Status:
COMPLETED
Antagonist Activation Measurement at the Ankle Using High-density and Bipolar Surface EMG in Chronic Hemiparesis
Lead Sponsor:
Henri Mondor University Hospital
Conditions:
Stroke
Muscle Hypertonia
Eligibility:
All Genders
18+ years
Brief Summary
In chronic hemiparesis, abnormal antagonist muscle activation in the paretic lower limb contributes to impair ambulation capacities. A biased estimate of antagonist muscle activation when using surfac...
Detailed Description
In chronic hemiparesis, gait velocity deficit is associated with a disturbed voluntary movement caused especially by inappropriate antagonist muscle activation. The present study investigates muscles ...
Eligibility Criteria
Inclusion
- hemiparesis due to a non-evolutive central nervous system lesion
- time since lesion ≥ 6 months
- ability to walk 10 meters barefoot without any assistance
- cognitive abilities to understand the verbal instructions for the test according to the investigator's judgment
- absence of botulinum toxin injections within the last 3 months prior to enrolment
Exclusion
- botulinum toxin injections within the last 3 months prior to enrolment
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06099132
Start Date
January 1 2017
End Date
December 31 2017
Last Update
October 25 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.